IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
2.210
+0.045 (2.08%)
Jul 16, 2025, 11:09 AM - Market open

Company Description

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.

Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.

The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer.

The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.

IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

IN8bio, Inc.
IN8bio logo
CountryUnited States
Founded2016
IPO DateJul 30, 2021
IndustryBiotechnology
SectorHealthcare
Employees18
CEOTai-Wei Ho

Contact Details

Address:
350 5th Avenue, Suite 5330
New York, New York 10118
United States
Phone646 600 6438
Websitein8bio.com

Stock Details

Ticker SymbolINAB
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$10.00
CIK Code0001740279
CUSIP Number45674E208
ISIN NumberUS45674E2081
Employer ID82-5462585
SIC Code2836

Key Executives

NamePosition
Tai-Wei HoCo-Founder, President, Chief Executive Officer and Director
Patrick McCall CPAChief Financial Officer and Secretary
Dr. Kate Rochlin Ph.D.Chief Operating Officer
Dr. Lawrence S. Lamb Ph.D.Executive Vice President, Co-Founder and Chief Scientific Officer

Latest SEC Filings

DateTypeTitle
Jun 30, 20258-KCurrent Report
Jun 4, 20258-KCurrent Report
Jun 2, 20258-KCurrent Report
May 9, 20258-KCurrent Report
May 8, 2025SCHEDULE 13D/AFiling
May 7, 202510-K/A[Amend] Annual report
May 7, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
Apr 29, 2025DEFR14AFiling
Apr 28, 20258-KCurrent Report